Glaxosmithkline Pharmaceuticals Ltd share price logo

Glaxosmithkline Pharmaceuticals Ltd

NSE: GLAXO

BSE: 500660

Mid Cap

Pharma Sector

2514.30

+19.30

(+0.77%)

as on

bell
The current prices are delayed by 15 mins, login to check live prices.

Glaxosmithkline Pharmaceuticals Stock Performance

as on July 24, 2026 at 9:31 pm IST

  • Day's Low

    Day's High

    ₹2,455.00
    ₹2,525.80
    downward going graph

    2.36%

    Downside

    0.46%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    ₹2,088.10
    ₹3,220.00
    downward going graph

    16.95%

    Downside

    28.07%

    Upside

    downward going graph

Glaxosmithkline Pharmaceuticals share price movements today

Previous Close
₹2,495.00
Open
₹2,490.20
Volume
63.79K
Upper Circuit
₹2,994.00
Lower Circuit
₹1,996.00
Day's Low - High
₹2,455.00 - ₹2,525.80
52 Week Low - High
₹2,088.10 - ₹3,220.00

Glaxosmithkline Pharmaceuticals Historical Returns

1 Month Return
+ 5.43 %
3 Month Return
+ 0.93 %
1 Year Return
-21.1 %
3 Year Return
+ 79.25 %
5 Year Return
+ 44.35 %

Glaxosmithkline Pharmaceuticals Fundamentals

as on July 24, 2026 at 4:01 pm IST

Market Cap

₹42,266.81 Cr

Return on Equity (ROE)

48.29

PE Ratio (TTM)

41.51

Return on capital employed (ROCE)

58.17

Industry PE ratio

48.98

Beta (LTM)

0.55

P/B Ratio

17.26

Dividend Yield

2.5

PEG Ratio

7.43

Quarterly Earnings Growth YOY

5.7

EPS (TTM)

61.15

Book Value

133.85

Glaxosmithkline Pharmaceuticals Stock Valuation

as on July 24, 2026 at 4:01 pm IST

Glaxosmithkline Pharmaceuticals in the last 5 years

  • Overview

  • Trends

Lowest (-81.64x)

December 28, 2020

Today (41.51x)

July 23, 2026

Industry (48.98x)

July 23, 2026

Highest (333.07x)

September 15, 2020

LowHigh

Today’s Price to Earnings Ratio: 41.51x

Glaxosmithkline Pharmaceuticals Technical Analysis

Track how Glaxosmithkline Pharmaceuticals technical analysis has moved over time to understand its trends.

1 min
5 min
15 min
30 min
1 day
1 week
1 month

Technicals Summary

Bearish

Neutral

Bullish

Bearish

Moving Averages

Bearish

Neutral

Bullish

Bullish

Oscillators

Bearish

Neutral

Bullish

Bearish

Overall

Bearish7
Bullish6
Neutral2

Oscillators

Name

Value

Action

MACD level (12,26)
3.07
Bearish
CCI (20)
-328.96
Bullish
RSI (14)
42.87
Neutral
Momentum (10)
-4.8
Bearish
ADI (14)
62.06
Bearish
Ultimate Oscillator (7,14,28)
64.38
Neutral

Moving Averages

Name

Value

Action

SMA (20)
2513.67
Bearish
EMA (20)
2512.55
Bearish
VWMA (20)
2514.64
Bearish
SMA (50)
2504.33
Bullish
EMA (50)
2504.89
Bullish
SMA (200)
2483.99
Bullish
EMA (200)
2489.67
Bullish
KAMA (200)
2512.4
Bearish
DEMA (200)
2495.09
Bullish

Glaxosmithkline Pharmaceuticals Ltd vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Glaxosmithkline Pharmaceuticals with its industry peers.

Company
Analyst View
Market Cap(in ₹ Cr)
5 Year CAGRDebt to Asset Ratio
Net Profit(in ₹ Cr)
Yearly Revenue(in ₹ Cr)
BUY42,266.818.87%0.001,0353,821
BUY7,817.07-11.5%0.004132,013
BUY88,479.3211.98%0.603,48331,723
BUY1,11,101.9816.79%0.695,02651,180
BUY60,966.2512.13%0.001,4146,445

Market expectation of Glaxosmithkline Pharmaceuticals Stock

Common consensus of the market based on various publicly available news, publications,brokerage expectation and market data

BUY

75.00%

Buy

25.00%

Hold

0.00%

Sell

Glaxosmithkline Pharmaceuticals Stock’s Investor Sentiment and Interest

Search interest for Glaxosmithkline Pharmaceuticals Ltd Stock has decreased by -35% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-35% versus previous 30 day period

Glaxosmithkline Pharmaceuticals Ltd Quarterly Profit & Loss

Figures in Rupees Crores

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Sales
956.99
805.26
929.8
814.65
1,010.77
949.42
974.37
805.17
979.94
1,041.26
995.3
Other Income
28.21
28.11
32.23
35.64
39.23
35.07
40.68
43.72
36.21
50.1
35.95
Total Income
985.2
833.37
962.03
850.29
1,050
984.49
1,015.05
848.89
1,016.15
1,091.36
1,031.25
Expenses
667.5
750.51
672.54
584.11
689.06
657.5
641.18
553.97
644.21
669.92
644.37
Operating Profit
289.49
54.75
257.26
230.54
321.71
291.92
333.19
251.2
335.73
371.34
350.93
Operating Profit Margin %
30.25%
6.8%
27.67%
28.3%
31.83%
30.75%
34.2%
31.2%
34.26%
35.66%
35.26%
Profit Before Interest, Tax and Depreciation
317.7
82.86
289.49
266.18
360.94
326.99
373.87
294.92
371.94
421.44
386.88
Interest
0.43
0.32
0.77
0.37
0.27
0.09
0.58
0.42
0.51
1.19
0.61
Depreciation
18.11
17.11
18.1
16.41
16.86
18.8
14.72
15.52
17.43
20.32
13.17
Profit Before Tax
299.16
65.43
270.62
249.4
343.81
308.1
358.57
278.98
354
399.93
373.1
Tax Paid
81.65
19.71
76.14
67.07
91.31
78.22
95.7
73.97
96.51
104.31
95.24
Profit After Tax
217.51
45.72
194.48
182.33
252.5
229.88
262.87
205.01
257.49
295.62
277.86
Total Net profit including share of profit / Loss from associate company
217.51
45.72
194.48
182.33
252.5
229.88
262.87
205.01
257.49
295.62
277.86
EPS
12.84
9.89
11.37
10.76
14.67
13.57
15.52
12.1
15.07
16.54
16.4
Actual EPS
12.84
9.89
11.37
10.76
14.67
13.57
15.52
12.1
15.07
16.54
16.4
Adjusted EPS
12.84
9.89
11.37
10.76
14.67
13.57
15.52
12.1
15.07
16.54
16.4
Diluted EPS
12.84
2.7
11.48
10.76
14.91
13.57
15.52
12.1
15.02
17.45
16.4

Glaxosmithkline Pharmaceuticals Ltd Annual Profit & Loss

Figures in Rupees Crores

Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
Sales
2,871.46
3,128.12
3,224.38
2,925.6
3,278.03
3,251.72
3,453.71
3,749.21
3,821.67
Other Income
72.34
131.01
79.01
181.46
1,401.31
103.71
122.59
150.62
165.98
Total Income
2,943.8
3,259.13
3,303.39
3,107.06
4,679.34
3,355.43
3,576.3
3,899.83
3,987.65
Expenses
2,365.65
2,527.33
2,908.62
2,500.06
2,516.15
2,448.4
2,688.63
2,571.85
2,512.47
Operating Profit
505.81
600.79
315.76
425.54
761.88
803.32
765.08
1,177.36
1,309.2
Operating Profit Margin %
17.62%
19.21%
9.79%
14.55%
23.24%
24.7%
22.15%
31.4%
34.26%
Profit Before Interest, Tax and Depreciation
578.15
731.8
394.77
607
2,163.19
907.03
887.67
1,327.98
1,475.18
Interest
0.19
0.55
6.34
3.53
2
1.81
1.8
1.31
2.73
Depreciation
37.99
48.59
82.68
78.6
68.19
65.77
69.68
66.79
66.44
Profit Before Tax
539.97
682.66
305.75
524.87
2,093
839.45
816.19
1,259.88
1,406.01
Tax Paid
189.25
237.27
212.55
166.72
398.28
228.76
226.23
332.3
370.03
Profit After Tax
350.72
445.39
93.2
358.15
1,694.72
610.69
589.96
927.58
1,035.98
Total Net profit including share of profit / Loss from associate company
350.72
445.39
93.2
358.15
1,694.72
610.69
589.96
927.58
1,035.98
EPS
41.41
26.29
5.5
21.14
100.04
36.08
41.14
54.52
60.11
Actual EPS
41.41
26.29
5.5
21.14
100.04
36.08
41.14
54.52
60.11
Adjusted EPS
20.71
26.29
5.5
21.14
100.04
36.08
41.14
54.52
60.11
Diluted EPS
41.41
26.29
5.5
21.14
100.04
36.05
34.83
54.76
61.15

Glaxosmithkline Pharmaceuticals Ltd Cash Flow

Figures in Rupees Crores

Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
Net Cash from Operating Activities
138.9
234.37
472.8
409.49
490.5
577.91
810.75
484.23
582.02
1,289.9
903.3
Cash Flow from Investing Activities
499.02
300.64
-104.19
-153.45
-56.84
418.02
-405.51
807.85
8.72
-45.8
396.99
Cash Flow from Financing Activities
-638.33
-510.76
-306.64
-358.36
-427.62
-695.55
-524.24
-1,543.33
-561.5
-769.42
-737.07
Net Cash Flow
-0.42
24.24
61.97
-102.33
6.03
300.38
-119
-251.25
29.23
474.68
563.2

Glaxosmithkline Pharmaceuticals Stock Shareholding Pattern

Numbers in percentages

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Promoters
75%
75%
75%
75%
75%
75%
75%
75%
75%
75%
75%
75%
DII
10.01%
8.53%
7.9%
7.5%
7.34%
7.3%
7.79%
7.7%
7.75%
7.7%
7.68%
7.8%
FII
0%
0%
3.48%
4.02%
4.36%
4.5%
4.52%
4.89%
4.8%
4.64%
4.62%
4.79%
Government
0.01%
0.01%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
Public
12.48%
13.43%
13.62%
13.48%
13.3%
13.19%
12.69%
12.41%
12.45%
12.66%
12.69%
12.41%
Total Outstanding Shares
16,94,06,034
16,94,06,034
16,94,06,034
16,94,06,034
16,94,06,034
16,94,06,034
16,94,06,034
16,94,06,034
16,94,06,034
16,94,06,034
16,94,06,034
16,94,06,034
Total Shareholders
1,15,266
1,14,663
1,18,994
1,18,515
1,19,228
1,19,625
1,21,885
1,23,629
1,22,904
1,22,460
1,21,763
1,26,087

Mutual Funds that own Glaxosmithkline Pharmaceuticals Stock

Check out the Mutual Funds with significant holdings in Glaxosmithkline Pharmaceuticals.

Glaxosmithkline Pharmaceuticals Corporate Actions

View detailed summary of the earnings and dividend history of Glaxosmithkline Pharmaceuticals.

  • Glaxosmithkline Pharmaceuticals Ltd Earnings Results

    Glaxosmithkline Pharmaceuticals Ltd’s net profit jumped 5.7% since last year same period to ₹277.86Cr in the Q4 2025-2026. On a quarterly growth basis, Glaxosmithkline Pharmaceuticals Ltd has generated -6.01% fall in its net profits since last 3-months.

    Read More about Earnings Results
  • Glaxosmithkline Pharmaceuticals Ltd Dividends May,2026

    In the quarter ending March 2026, Glaxosmithkline Pharmaceuticals Ltd has declared dividend of ₹57.00 per share on 13 May 2026 - translating a dividend yield of 3.97%.

    Read More about Dividends

Indices Featuring Glaxosmithkline Pharmaceuticals Stock

Check stock indices that include Glaxosmithkline Pharmaceuticals.

BSE Healthcare

₹49,395.81

-160.95 (0.32%)

S&P BSE Quality

₹1,868.12

-10.73 (0.57%)

S&P BSE 250 LargeMidCap

₹10,612.28

-35.30 (0.33%)

BSE 200

₹11,144.69

-38.58 (0.34%)

BSE 500

₹35,829.46

-115.20 (0.32%)

Nifty MidSmallcap 400

₹20,831.30

-32.25 (0.15%)

S&P BSE 400 MidSmallCap

₹12,422.53

-22.65 (0.18%)

Nifty LargeMidcap 250

₹16,419.45

-37.55 (0.23%)

Nifty Midcap 150

₹22,685.25

-20.00 (0.09%)

S&P BSE 150 MidCap

₹16,683.27

-26.60 (0.16%)

Nifty 500

₹22,913.30

-69.10 (0.30%)

Insights on Glaxosmithkline Pharmaceuticals Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 4.73% to 4.87% in Jun 2026 quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, GLAXO stock has moved up by 5.4%

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 4.62% to 4.79% in Jun 2026 quarter

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 75.00% of holdings in Jun 2026 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Torrent Pharmaceuticals Ltd has given 43.9% return, outperforming this stock by 65.0%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Torrent Pharmaceuticals Ltd has given 161.0% return, outperforming this stock by 81.7%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 1.09K Cr → 1.03K Cr (in ₹), with an average decrease of 5.5% per quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 295.62 Cr → 277.86 Cr (in ₹), with an average decrease of 6.0% per quarter

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 12.69% to 12.41% in Jun 2026 quarter

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UKbased GSK Plc. a global biopharma company to unite science technology and talent to get ahead of disease together. The Company is headquartered in Mumbai and it has six branch offices a manufacturing facility at Nashik in Maharashtra 22 contract manufacturing organisations CMOs with regional and sales hubs across India. The Company is engaged interalia in the business of manufacturing distributing and trading in pharmaceuticals.The Companys portfolio includes General Medicines Vaccines and Specialty medicines that help prevent and treat disease. Their prescription medicines range across therapeutic areas such as AntiInfectives Dermatology Gynaecology Diabetes Oncology Cardiovascular Disease and Respiratory Diseases. They also offer a range of vaccines for the prevention of Hepatitis A Hepatitis B Invasive Disease caused by H Influenza Chickenpox Diphtheria Pertussis Tetanus Rotavirus Cervical Cancer and Others. They have two manufacturing units in India located at Nashik and Thane. Also they have a clinical development centre in Bangalore. GlaxoSmithKline Pharma Limited was incorporated in November 13 1924. During year 1956 the Company began primary production of vaccines at Worli. In the year 1960 the company started manufacturing Infant foods at milk drying plant at Aligarh. They also opened manufacturing facility for pharmaceuticals in Mumbai. In 1961 the Company started manufacturing Vitamin A and Betamethasone at new plant at Thane using imported raw materials. The Company registered as a limited company in the year 1968. Also they introduced the Animal health products. In the year 1971 the company built the Research development laboratory at Thane. Also they relocated the SmithKline French plant from Mumbai to Bangalore. In the year 1983 they commissioned the Nashik factory. SmithKline Beecham became a public limited company under the new name of Eskayef Ltd in the year 1984 and one new Plant was set up in Mysore for manufacture of bulk drugs. In the year 1985 the companys second basic drugs factory was inaugurated at Ankleshwar Gujarat. In the year 1986 the company launched joint venture projects Vegepro Foods and Feeds Ltd and K G Gluco Biols. The companys name was changed to Glindia Ltd in the year 1987. In the year 1988 the company commenced the production of bulk drug Ranitidine at Ankleshwar. Also they started a joint venture project with Hindustan Foods Ltd for the manufacture of extruded foods at Usgao Goa. In the year 1989 the company commenced their Zinetac production at Nashik. The companys name was changed from Glindia Ltd to Glaxo India Ltd. In the year 1990 the production of the bulk drug cephalexin was commenced at Ankleshwar and the salbutamol inhalers at Nashik. Glaxo rated amongst the first five of Indias most respected companies 4th place in a survey by Businessworld magazine. An agreement was signed with the Council of Scientific and Industrial Research CSIR during 1991. In the year 1992 the company sold their trade investments in Vegepro and Feeds Ltd. In the year 1993 they sold their investment in Hindustan Foods Ltd and Dempo Dairy Industries Ltd. Cetzine a secondgeneration antihistamine and research product of UCB Pharma Belgium was launched under a comarketing agreement. In the same year Glaxo received recognition from the Ministry of Commerce as an export house. In the year 1994 the company sold their Family Products Division to H J Heinz for a sum of Rs 210 crore. The Mysore plant received ISO 9002 certification and the new Iodex plant was inaugurated in Bangalore. In the year 1995 they inaugurated the government approved stateoftheart Pharmacy Research Development Centre PRD at Thane to cater to the unmet medical needs and to exploit local commercial opportunities.In the year 1998 the company acquired Biddle Sawyer Group of Companies which was struggled in the year before. In the year 2000 Agrivet Farm Care AFC tied up with Merial the worlds largest Animal Health Company to market poultry vaccines. The company ranked 6th in Business Today Stern Stewart Co. listing of Indias best Wealth Creator Companies and also the launched Seretide for Asthma. The merger of SmithKline Beecham Pharmaceuticals India Ltd into Glaxo India Limited was completed and the name of the company was changed to the present name GlaxoSmithKline Pharmaceuticals Ltd. Businessworld and the Indian Market Research Bureau IMRB named GlaxoSmithKline as Indias most respected Pharmaceutical Company in a survey in the year 2003. During the year the company launched Cetzine Cetirizine antihistamine Zimig terbinafine antiinfective CCM calcium citrate maleate nutritional Cobadex CZS multivitamin with trace elements.In the year 2004 the company launched Priorix measles mumps rubella vaccine. In the year 2005 the company launched oral contraceptives: Elogen desogestrel and ethinylestradiol and Zerogen progesterone only pill. They entered into the diabetes therapeutic segment with the launch of Windia rosiglitazone and Windamet rosiglitazone and metformin. In the year 2006 the company made an inlicensing alliance with Eisai Pharmaceuticals Japan and launched Parit rabeprazole gastrointestinal therapy area. Also GlaxoSmithKline divested their Agrivet Farm Care AFC animal health business. In the year 2007 the company launched Carzec carvedilol and Zemetril cefprozil.

Revenue: ₹995.30Cr as on March 2026 (Q4 FY26)
Net Profit: ₹277.86Cr as on March 2026 (Q4 FY26)
Listing date: 03 Nov, 1994
Chairperson Name: Renu S Karnad
OrganisationGlaxosmithkline Pharmaceuticals Ltd
IndustryPharmaceuticals
CEORenu S Karnad
E-voting on sharesClick here to vote

FAQs

What is Glaxosmithkline Pharmaceuticals share price today?

Glaxosmithkline Pharmaceuticals share price today stands at ₹2514.3 as on at the close of the market. Glaxosmithkline Pharmaceuticals share today touched a day high of ₹2525.8 and a low of ₹2455.

What is the 52 week high and 52 week low range for Glaxosmithkline Pharmaceuticals share?

Glaxosmithkline Pharmaceuticals touched a 52 week high of ₹3220 and a 52 week low of ₹2088.1. Glaxosmithkline Pharmaceuticals share price today i.e. is closed at ₹2514.3, which is -21.92% down from its 52 week high and 20.41% up from its 52 week low.

What is Glaxosmithkline Pharmaceuticals's market capitalisation today?

Glaxosmithkline Pharmaceuticals market capitalisation is ₹42,266.81 Cr as on .

How to buy Glaxosmithkline Pharmaceuticals shares?

To buy Glaxosmithkline Pharmaceuticals shares, you need to follow these steps:

  • Open a Demat account and Trading account on INDmoney
  • Fund your Trading account
  • Search for GLAXO or Glaxosmithkline Pharmaceuticals Ltd on the INDmoney app to check live prices of the stock
  • Click on Buy or SIP to place an order to invest in Glaxosmithkline Pharmaceuticals shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.

What is Glaxosmithkline Pharmaceuticals trading volume today?

Glaxosmithkline Pharmaceuticals trading volume is 63.79K as on . This means that 63.79K shares of Glaxosmithkline Pharmaceuticals were bought and sold on the stock market during today's trading session.